Products

Blinatumomab (TAB-728)

Recombinant Bi-specific T-cell engager expressed in CHO binding to human CD19. Blinatumomab is a drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodiess, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.      

Specifications
Immunogen
The details of the immunogen for this antibody are not available.
Host
Mouse
Derivation
Mouse
Type
(scFv - kappa - heavy) - (scFv - heavy - kappa)
Species Reactivity
Human
Applications
Suitable for use in IF, IP, Neut, FuncS, ELISA, FC, ICC and most other immunological methods.
CAS NO.
853426-35-4
Generic Name
Blinatumomab
Biological Half-Life
2.11 hours
UNII
4FR53SIF3A
M.W.
54.1 kDa
Related Disease
Acute lymphocytic leukemia (ALL)
Target
Alternative Names
Blinatumomab; 853426-35-4; AMG 103; MEDI-538; MT-103; MT103; BscCD19xCD3; Blincyto
Entrez Gene ID
930
UniProt ID
P15391

For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Send Inquiry Now!
Name:
* Phone:
* E-mail Address:
* Service & Products Interested:
Project Description:
* Verification Code:
Please input "biolabs"(case insensitive) as verification code.
Contact Us to Order
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email:

45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-381-2994    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2018 Creative-Biolabs All Rights Reserved